The stock of BridgeBio Pharma Inc (BBIO) has seen a 19.95% increase in the past week, with a 16.15% gain in the past month, and a 35.14% flourish in the past quarter. The volatility ratio for the week is 7.11%, and the volatility levels for the past 30 days are at 4.92% for BBIO. The simple moving average for the past 20 days is 19.93% for BBIO’s stock, with a 26.71% simple moving average for the past 200 days.
Is It Worth Investing in BridgeBio Pharma Inc (NASDAQ: BBIO) Right Now?
Moreover, the 36-month beta value for BBIO is 1.04. Analysts have varying opinions on the stock, with 9 analysts rating it as a “buy,” 6 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for BBIO is 147.77M and currently, short sellers hold a 13.06% of that float. On January 14, 2025, BBIO’s average trading volume was 1.94M shares.
BBIO) stock’s latest price update
BridgeBio Pharma Inc (NASDAQ: BBIO)’s stock price has plunge by 15.99relation to previous closing price of 29.08. Nevertheless, the company has seen a 19.95% surge in its stock price over the last five trading sessions. investors.com reported 2025-01-13 that Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.
Analysts’ Opinion of BBIO
Piper Sandler gave a rating of “Overweight” to BBIO, setting the target price at $46 in the report published on September 04th of the previous year.
BBIO Trading at 26.43% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.81% of loss for the given period.
Volatility was left at 4.92%, however, over the last 30 days, the volatility rate increased by 7.11%, as shares surge +16.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.67% upper at present.
During the last 5 trading sessions, BBIO rose by +19.95%, which changed the moving average for the period of 200-days by +13.34% in comparison to the 20-day moving average, which settled at $28.13. In addition, BridgeBio Pharma Inc saw 22.92% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from Kumar Neil, who sale 27,389 shares at the price of $22.41 back on Nov 19 ’24. After this action, Kumar Neil now owns 4,897,443 shares of BridgeBio Pharma Inc, valued at $613,826 using the latest closing price.
STEPHENSON BRIAN C, the Secretary, Treasurer & CFO of BridgeBio Pharma Inc, sale 4,156 shares at $22.41 during a trade that took place back on Nov 19 ’24, which means that STEPHENSON BRIAN C is holding 93,758 shares at $93,137 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -2.48 for the present operating margin
- 0.98 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -2.02. The total capital return value is set at -1.03.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated 3.51 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at -1.4. The interest coverage ratio of the stock is -6.03.
Currently, EBITDA for the company is -565.47 million with net debt to EBITDA at -4.18. When we switch over and look at the enterprise to sales, we see a ratio of 35.99. The receivables turnover for the company is 455.58for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.19.
Conclusion
To wrap up, the performance of BridgeBio Pharma Inc (BBIO) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
